Evidence map›Paper›PMID 40843787›Full record

ArticleVision (Basel, Switzerland)2025

Case Series: Reactivation of Herpetic Keratitis After COVID-19 mRNA Vaccination During Herpetic Prophylaxis.

Michael Tsatsos, Efthymia Prousali, Athanasios Karamitsos, Nikolaos Ziakas

Abstract read
In one paragraph

Article in Vision (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael Tsatsos2nd Ophthalmology Department, Aristotle University of Thessaloniki, Papageorgiou Hospital, Ag. Pavlou 76, 56429 Thessaloniki, Greece.ORCID 0000-0003-1280-4113
Efthymia Prousali2nd Ophthalmology Department, Aristotle University of Thessaloniki, Papageorgiou Hospital, Ag. Pavlou 76, 56429 Thessaloniki, Greece.
Athanasios Karamitsos2nd Ophthalmology Department, Aristotle University of Thessaloniki, Papageorgiou Hospital, Ag. Pavlou 76, 56429 Thessaloniki, Greece.ORCID 0000-0002-1692-7690
Nikolaos Ziakas2nd Ophthalmology Department, Aristotle University of Thessaloniki, Papageorgiou Hospital, Ag. Pavlou 76, 56429 Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report presents two cases of herpes simplex keratitis recurrence after COVID-19 mRNA vaccination in patients on herpetic prophylaxis due to recurrent herpetic keratitis. A 58-year-old man with a history of a previous penetrating keratoplasty presented with blurred vision and evidence of corneal endothelitis 48 h after the first dose of the m-RNA vaccination, and a 24-year-old male student came with a dendritic ulcer 72 h post first vaccination dose. The original prophylactic treatment of 400 mg of acyclovir twice daily was increased to five times per day for a week for both patients. The grafted patient additionally received an increase in Dexamethasone 0.1% from twice daily to four times a day. Improvement was noted within two days and documented at the weekly review, during which both patients returned to their prophylactic antiviral regime without further recurrence. At the time of their second dose of vaccination, both patients followed the same regime with an increase in treatment as per the first dose of vaccination without recurrence. Our findings suggest that patients with recurrent herpetic disease receiving prophylactic treatment need close monitoring when experiencing even subtle symptoms of recurrence and may benefit from an increase in their dose to therapeutic levels during the first days after the COVID-19 mRNA vaccination.

Indexed as

COVID-19herpetic keratitis recurrenceherpetic prophylaxisvaccination

Identifiers

PMID40843787
PMCPMC12372037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.